(Q36972046)

English

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer

scientific article published on 03 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer (English)

1 reference

Europe PubMed Central

17 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A J Montero

1

1 reference

Europe PubMed Central

17 August 2017

C M Diaz-Montero

2

1 reference

Europe PubMed Central

17 August 2017

Y E Deutsch

3

1 reference

Europe PubMed Central

17 August 2017

J Hurley

4

1 reference

Europe PubMed Central

17 August 2017

L G Koniaris

5

1 reference

Europe PubMed Central

17 August 2017

T Rumboldt

6

1 reference

Europe PubMed Central

17 August 2017

S Yasir

7

1 reference

Europe PubMed Central

17 August 2017

M Jorda

8

1 reference

Europe PubMed Central

17 August 2017

E Garret-Mayer

9

1 reference

Europe PubMed Central

17 August 2017

E Avisar

10

1 reference

Europe PubMed Central

17 August 2017

J Slingerland

11

1 reference

Europe PubMed Central

17 August 2017

O Silva

12

1 reference

Europe PubMed Central

17 August 2017

C Welsh

13

1 reference

Europe PubMed Central

17 August 2017

K Schuhwerk

14

1 reference

Europe PubMed Central

17 August 2017

P Seo

15

1 reference

Europe PubMed Central

17 August 2017

M D Pegram

16

1 reference

Europe PubMed Central

17 August 2017

S Glück

17

1 reference

Europe PubMed Central

17 August 2017

language of work or name

0 references

publication date

3 December 2011

1 reference

Europe PubMed Central

17 August 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

17 August 2017

132

1 reference

Europe PubMed Central

17 August 2017

215-223

1 reference

Europe PubMed Central

17 August 2017

1

1 reference

Europe PubMed Central

17 August 2017

https://scigraph.springernature.com/pub.10.1007/s10549-011-1889-0

0 references

Cellular redox pathways as a therapeutic target in the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Redox-directed cancer therapeutics: molecular mechanisms and opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Immunogenic cancer cell death: a key-lock paradigm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Redox regulation of cell survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Proper inference from Simon's two-stage designs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

The redox regulation of thiol dependent signaling pathways in cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Glutathione peroxidases and redox-regulated transcription factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Docetaxel for treatment of solid tumours: a systematic review of clinical data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Controlling tumor growth by modulating endogenous production of reactive oxygen species.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

29 September 2017

Pharmacology of a mimetic of glutathione disulfide, NOV-002.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

27 June 2018

Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

4 September 2018

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

4 September 2018

Lymphopenia associated with adjuvant anthracycline/ taxane regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

4 September 2018

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

4 September 2018

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

4 September 2018

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

4 September 2018

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3697917

4 September 2018

NOV-002, a mimetic of glutathione disulfide

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1889-0

21 January 2018

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/22138748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://pubmed.ncbi.nlm.nih.gov/22138748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22138748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/22138748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

https://pubmed.ncbi.nlm.nih.gov/22138748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22138748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-011-1889-0

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36972046&oldid=1665012180"